Filing Details

Accession Number:
0001246360-14-003716
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-09-04 17:21:10
Reporting Period:
2014-09-02
Filing Date:
2014-09-04
Accepted Time:
2014-09-04 17:21:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
911326 Synageva Biopharma Corp GEVA Biological Products, (No Disgnostic Substances) (2836) 561808663
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1532219 Anthony Quinn 33 Hayden Ave
Lexington MA 02421
Evp, Cmo & Head Of R&D No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-09-02 10,000 $23.00 35,595 No 4 M Direct
Common Stock Disposition 2014-09-02 8,600 $69.88 26,995 No 4 S Direct
Common Stock Disposition 2014-09-02 400 $70.50 26,595 No 4 S Direct
Common Stock Disposition 2014-09-02 700 $71.96 25,895 No 4 S Direct
Common Stock Disposition 2014-09-02 300 $72.88 25,595 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2014-09-02 10,000 $0.00 10,000 $23.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
30,000 2021-12-20 No 4 M Direct
Footnotes
  1. The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 26, 2013.
  2. The Stock Option granted the reporting person an option to purchase 50,000 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 12/20/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter.
  3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $69.46 to $70.38. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
  4. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $70.47 to $70.55. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
  5. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $71.47 to $72.16. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
  6. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $72.69 to $73.04. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.